Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare extra-lipid effects of statins and fibrates in relation to the baseline metabolic status of patients. RESEARCH DESIGN AND METHODS: The study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo. RESULTS: Compared with matched healthy subjects, metabolic syndrome patients exhibited higher plasma levels/activities of high-sensitivity C-reactive protein (hs-CRP), fibrinogen, factor VII, plasminogen activator inhibitor 1, and enhanced monocyte cytokine release. These abnormalities were alleviated by both atorvastatin and fenofibrate treatment. CRP-lowering and monocyte-suppressing actions were more pronounced for atorvastatin in subjects with impaired fasting glucose and for fenofibrate in patients with impaired glucose tolerance. CONCLUSIONS: The presence of pre-diabetes potentiates metabolic syndrome–induced abnormalities in plasma markers of inflammation and hemostasis and in monocyte secretory function. Both atorvastatin and fenofibrate exhibit multidirectional pleiotropic effects in subjects with metabolic syndrome, the strength of which seem to be partially determined by the type of pre-diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.dec.s253-s259 · Cited by 264
Petersen, J. L., & McGuire, D. K. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.007 · Cited by 159
Pleiotropic effects of statins–clinical evidence.
Athyros, V., Kakafika, A., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315729 · Cited by 154 · cited 1×
“nti-inflammatory, endothelialprotective, antioxidant and anti-thrombotic actions of statins and fibrates are observed not only in patients with dyslipidemia (1-5) but also in subjects with early and late glucose metabolism abnormalities (6-8).”
Cited by
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Fibrates for primary prevention of cardiovascular disease events
Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147
PAI-1 and diabetes: a journey from the bench to the bedside
Schneider, D. J., & Sobel, B. E. (2012) · Diabetes Care · doi:10.2337/dc12-0638 · Cited by 78
“Agents that decrease concentrations of triglycerides in blood such as atorvastatin and gemfibrozil reduce concentrations of PAI-1 in blood from patients with insulin-resistant states (41).”
BackgroundAlvarez-Jimenez, L., Morales-Palomo, F., Moreno-Cabañas, A., Ortega, J. F., & Mora-Rodríguez, R. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175672 · Cited by 60
Metadata
- Authors
- Krysiak, R., Gdula-Dymek, A., Bachowski, R., & Okopień, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-06-29
- Volume
- 33
- Issue
- 10
- Pages
- 2266-2270
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2101062926
- Cited by
- 69
- References
- 3
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes. https://app.cochat.ai/papers/10.2337/dc10-0272
- The paper
- Krysiak, R., Gdula-Dymek, A., Bachowski, R., & Okopień, B. (2010). Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes. Diabetes Care. https://doi.org/10.2337/dc10-0272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.